3 New Strong Buy Ratings from Top-Rated Analysts: 05/05/2026

Need some investing inspo? Start with these 3 picks, sourced from our most popular screener:

• Eli Lilly & Co (LLY) — GLP-1 dominance fuels record-breaking obesity drug momentum.
• Cardinal Health Inc (CAH) — Dividend hike and earnings beat signal continued strength.
• Dexcom Inc (DXCM) — CGM leader posts Q1 beat with expanding margins.

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

An urgent warning for all U.S. Investors...

"Will You Be On The Right Side Of the Great AI Divide?"

Legendary investment strategist from America's oldest and largest private investment research club bought (split-adjusted) Apple at $1... Netflix at $1.62... Amazon under $2.

Now he's speaking out about 3 AI super-cycle stocks that could dominate the markets.

GET THE FULL STORY HERE

1. Cardinal Health Inc (NYSE: CAH)

Cardinal Health supplies 75% of U.S. hospitals and reigns atop the Medical Distribution industry. Fresh off a dividend hike and a Q3 earnings beat, management raised full-year guidance — fueling what analysts are calling the "Golden Era" of healthcare distribution.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $195.24 — get current quote

Max 1-year forecast: $258.00

Why we're watching:

• Analyst support: Strong consensus with 5 Strong Buy ratings, 2 Buy ratings, and only 1 Hold rating among 8 analysts covering the stock. See the ratings
• Morgan Stanley's Erin Wright (a top 6% rated analyst) maintains a Strong Buy rating with a $245 price target, predicting that the "Golden Era" of healthcare distribution will continue with group multiple expansion visible against a "robust backdrop" in which the group enjoys "relative policy insulation."
• JP Morgan's Lisa Gill (a top 18% rated analyst) holds a $243 price target, noting the company's strategic positioning within a favorable regulatory environment and improving distribution economics.
• Analysts recently maintained their bullish stance following CAH's Q3 earnings beat, with the company raising its FY 2026 EPS outlook despite a slight revenue miss, demonstrating strong operational execution and margin expansion.
• Industry ranking context: CAH is currently the 1st highest-rated stock in the Medical Distribution industry, which has an Industry Rating of A.
• Zen Rating highlights: CAH is in the highest tier of stocks we track based on a 115-factor due diligence review, earning an overall rating of A (Strong Buy).
• Component Grades: CAH shows balanced strength with A-grade Sentiment, B-grades in Growth and Safety, reflecting strong analyst confidence, solid growth trajectory, and financial stability in a defensive healthcare sector. See all 7 Zen Component Grades here

2. Dexcom Inc (NASDAQ: DXCM)

With a $23.67B market cap and industry-leading continuous glucose monitoring (CGM) technology, DexCom is transforming diabetes care worldwide. A Q1 2026 earnings and revenue beat — paired with expanding margins and reaffirmed guidance — proves demand for its innovative devices isn't slowing down.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $61.35 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: Overwhelming bullish sentiment with 9 Strong Buy ratings, 2 Buy ratings, 1 Hold, and 1 Strong Sell among 13 analysts, demonstrating strong conviction in DXCM's growth trajectory. See the ratings
• Citigroup's Joanne Wuensch (a top 10% rated analyst) maintains a Strong Buy rating with an $84 price target (+36.92% upside), expressing confidence in the company's technological leadership and market expansion potential.
• Mizuho's Anthony Petrone (a top 12% rated analyst) maintains a Buy rating with a $90 price target (+46.70% upside), highlighting the company's innovative product pipeline and strong competitive positioning in the CGM market.
• Truist Securities' Richard Newitter (a top 17% rated analyst) reiterates a Strong Buy with an $80 price target (+30.40% upside), citing DexCom's technological advantages and expanding addressable market as key growth drivers.
• Industry ranking context: DXCM is currently the 8th highest-rated stock in the Medical Device industry, which has an Industry Rating of C, making DXCM a standout performer in its sector.
• Zen Rating highlights: As a Strong Buy-rated stock, DXCM is in a class of stocks that have historically generated over 30% in annual returns. 
• Component Grades: DXCM excels with an A-grade in Financials, and B-grades in Value and AI, reflecting robust financial health and a potentially attractive valuation. See all 7 Zen Component Grades here

3. Eli Lilly & Co (NYSE: LLY)

A $907B pharmaceutical juggernaut, Eli Lilly is dominating the obesity and diabetes race with its blockbuster GLP-1 portfolio. New oral obesity drug launches are widening its competitive moat — prescriptions are surging, and a recent double-beat earnings report cements its market leadership.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $963.33 — get current quote

Max 1-year forecast: $1,500.00

Why we're watching:

• Analyst support: Wall Street is decisively bullish with 13 Strong Buy ratings, 4 Buy ratings, and just 1 Sell rating among 18 analysts covering the stock. See the ratings
• Guggenheim's Seamus Fernandez (a top 3% rated analyst) maintains his Strong Buy rating with a $1,183 price target, emphasizing strong fundamentals underpinning LLY's valuation following the company's innovative drug pipeline and positive FDA outlook.
• Morgan Stanley's Terence Flynn (a top 8% rated analyst) projects a $1,327 price target (+37.75% upside), expressing optimism about LLY's strategic positioning in emerging markets and the company's expansion into new therapeutic areas with innovative therapies.
• RBC Capital's Trung Huynh (a top 10% rated analyst) recently initiated coverage with a Buy rating and $1,250 price target, highlighting LLY's robust pipeline as a key driver for future growth, citing R&D breakthroughs and strategic partnerships as major catalysts.
• Industry ranking context: LLY is currently the 3rd highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
• Zen Rating highlights: Strong Buy (A) stocks have historically averaged +32.52% returns annually, positioning LLY among elite opportunities with substantial upside potential.
• Component Grades: LLY demonstrates exceptional strength with an A-grade Sentiment component and B-grades in Value, Financials, and Artificial Intelligence, reflecting strong analyst conviction, solid fundamentals, and innovative technological integration. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.